Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Epitalon (Epithalon) | LL-37 (Cathelicidin) | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 5-10 mg daily via subcutaneous injection for 10-20 day cycles. | Research indicates 50-100 mcg daily via subcutaneous injection for immune support. |
| Timing | Evening administration preferred (aligns with pineal/melatonin function). Some protocols split doses AM/PM. | Morning administration preferred for immune support. Topical application directly to wound sites. |
| Cycle Duration | 10-20 day intensive cycles repeated every 4-6 months. Not used continuously. | 4-8 week cycles. Short-term use preferred due to limited long-term safety data. |
| Evidence Level | animal_plus_anecdotal | animal_plus_anecdotal |
Epitalon (Ala-Glu-Asp-Gly / AEDG) is a synthetic tetrapeptide based on the natural pineal gland peptide epithalamin. It activates telomerase by inducing expression of the catalytic subunit hTERT, resulting in telomere elongation averaging 33.3% in human somatic cells. Epitalon restores pineal melatonin synthesis and circadian gene expression in aged organisms, increases BDNF, and upregulates CREB1. It also modulates the neuroendocrine system through its effects on the hypothalamic-pituitary axis and antioxidant enzyme regulation.
Research indicates 5-10 mg daily via subcutaneous injection for 10-20 day cycles.
Evening administration preferred (aligns with pineal/melatonin function). Some protocols split doses AM/PM.
10-20 day intensive cycles repeated every 4-6 months. Not used continuously.
LL-37 is a 37-residue amphipathic helical antimicrobial peptide, the only human cathelicidin, that kills bacteria by forming tetrameric channels that perforate cytoplasmic membranes. Beyond direct antimicrobial activity, it modulates innate immunity through formyl-peptide receptor 2 (FPR2), induces chemotaxis of neutrophils and monocytes, upregulates CXCR4 and IL-8, and neutralizes bacterial endotoxins (LPS). It also promotes wound healing through keratinocyte migration and angiogenesis.
Research indicates 50-100 mcg daily via subcutaneous injection for immune support.
Morning administration preferred for immune support. Topical application directly to wound sites.
4-8 week cycles. Short-term use preferred due to limited long-term safety data.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →